Mission Cancer + Blood

Clinical Trials

Prostate D9723C00001

Study #D9723C00001

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician’s Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)

Description
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician’s choice NHA relative to placebo + physician’s choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Principal investigator: Dr. Zeeshan Jawa

Sponsor: AstraZeneca

Interested in this trial? Email [email protected].

Back To Clinical Trials NCI Database Entry